Respiri (ASX:RSH) to sell wheezo over Sigma network

Company News

by Adrian Tan

EHealth company Respiri (ASX:RSH) has announced the commencement of sales of wheezo across over 570 pharmacies within the Sigma Healthcare (ASX:SIG) network.

The wheezo asthma-management system consists of an app and a handheld device. Wheezo provides objective and ongoing monitoring of asthma symptoms, and can record and analyse 30 seconds of breath for the presence of wheeze. Additional features include the abilities to set reminders, to track triggers and medication, and to share data with health professionals.

Sigma is the owner of pharmacy brands Amcal, Chemist King, Discount Drug Store, Guardian, Pharmasave and Wholelife.

Shares in Respiri (ASX:RSH) are trading 10 per cent higher at $0.08.

Image from:

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.